Eli Lilly's (LLY) GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list.

Yahoo Finance Senior Health Reporter Anjalee Khemlani reports more on the story and what it means for competitors, like Novo Nordisk (NVO).

For more expert insight and the latest market action, click here to watch this full episode of Catalysts.

This post was written by Melanie Riehl